The Anti-Infective Vaccines Market Report 2022-2032: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.
Growing Burden of Infectious Disease Likely to Boost Market Growth Through 2032
The majority of infectious diseases place a social and financial strain on society. For instance, influenza affects millions of people every year, which leads to decreased productivity and economic losses. Furthermore, each year, up to 200,000 people are hospitalized due to influenza. Governments have been compelled to acknowledge the severity of influenza as a serious infection that leads to healthcare expenses and a burden on government bodies.
The same is true for the various infectious diseases that can be avoided with vaccination, including hepatitis, pneumococcal, and meningitis among other infectious diseases. To enhance vaccination coverage rates among youngsters, the elderly, and the working adults who drive the economy, local governments are strategizing on expanding their vaccination programs. For instance, in India, the United Nations International Children’s Emergency Fund (UNICEF) in collaboration with the Ministry of Health and Family Welfare (MoHFW) will enhance vaccination immunization coverage across the Indian region.
Research and Development on Therapeutic Vaccines will lead to Ground-Breaking Discoveries
Research and development on therapeutic vaccines will lead to ground-breaking discoveries and fill medical demands that have not yet been satisfied. Additional novel vaccine development techniques will result from this. New target sites, strategies for inducing an immune response, and delivery techniques are all being studied and, in some cases, successfully implemented. As businesses look for innovative ways to get a competitive edge over their rivals, which could simply be a new method of administering an outdated immunization mode of delivery will boost the market growth
A major issue for the human vaccine industry is the expense of vaccine production. The development of vaccines requires a great deal of expertise and work. A vaccine must go through a lengthy development process that includes numerous trial phases and regulatory approval before it can be commercialized. This indicates that creating a vaccine with a sizable market and the capacity to make a profit accounts for a top priority for manufacturers. The long-term focus of these manufacturers will be on implementing structural reforms in the industry that can lower prices without compromising vaccine effectiveness and quality because this will continue to be a problem in the years to come.
What Questions Should You Ask before Buying a Market Research Report?
• How is the Anti-Infective Vaccines Market evolving?
• What is driving and restraining the Anti-Infective Vaccines Market?
• How will each Anti-Infective Vaccines submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2032?
• How will the market shares for each Anti-Infective Vaccines submarket develop from 2022 to 2032?
• What will be the main driver for the overall market from 2022 to 2032?
• Will leading Anti-Infective Vaccines markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
• How will the market shares of the national markets change by 2032 and which geographical region will lead the market in 2032?
• Who are the leading players and what are their prospects over the forecast period?
• What are The Anti-Infective Vaccines projects for these leading companies?
• How will the industry evolve during the period between 2020 and 2032? What are the implications of anti-infective vaccine projects taking place now and over the next 10 years?
• Is there a greater need for product commercialization to further scale the Anti-Infective Vaccines Market?
• Where is the Anti-Infective Vaccines Market heading and how can you ensure you are at the forefront of the market?
• What are the best investment options for new product and service lines?
• What are the key prospects for moving companies into a new growth path and C-suite?
You need to discover how this will impact the Anti-Infective Vaccines Market today, and over the next 10 years:
• Our 270-page report provides 108 tables and 170 charts/graphs exclusively to you.
• The report highlights key lucrative areas in the industry so you can target them – NOW.
• It contains in-depth analysis of global, regional and national sales and growth.
• It highlights for you the key successful trends, changes and revenue projections made by your competitors.
This report tells you TODAY how the Anti-Infective Vaccines Market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.
The report delivers exclusive COVID-19 variations and economic data specific to your market.
To access the data contained in this document please email contactus@visiongain.com
Forecasts to 2032 and other analyses reveal commercial prospects
• In addition to revenue forecasting to 2032, our new study provides you with recent results, growth rates, and market shares.
• You will find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising anti-infective vaccines prices and recent developments.
This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, “V”, “L”, “W” and “U” are discussed in this report.
Segments Covered in the Report
Disease Type
• Bacterial Diseases
– Typhoid Vaccines
– Tuberculosis Vaccines
– Tetanus & Diphtheria Vaccines
– Others
• Viral Diseases
– Influenza Vaccines
– Hepatitis Vaccines
– Polio Vaccine
– Others
Product
• Live/Attenuated Vaccines
• Inactivated Vaccines
• DNA & Recombinant Vector Vaccines
• Others
Distribution Channel
• Hospital Pharmacy
• Retail Pharmacy
• Others
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for four regional and 20 leading national markets:
North America
• U.S.
• Canada
Europe
• Germany
• France
• UK
• Italy
• Spain
• Russia
• Rest of Europe
Asia Pacific
• China
• Japan
• India
• Australia
• Rest of Asia Pacific
Latin America
• Brazil
• Mexico
• Rest of Latin America
MEA
• GCC
• South Africa
• Rest of MEA
Need industry data? Please contact us today.
The report also includes profiles and for some of the leading companies in the Anti-infective Vaccines Market, 2022 to 2032, with a focus on this segment of these companies’ operations.
Leading companies and the potential for market growth
• AstraZeneca
• Bavarian Nordic
• BioDiem
• CSL Limited
• Emergent BioSolutions Inc.
• Evotec
• Merck & Co, Inc.
• Mitsubishi Tanabe Pharma Corporation
• Pfizer
• Serum Institute of India Pvt. Ltd.
• Sinovac Biotech Ltd.
• Valneva SE
Overall world revenue for Anti-infective Vaccines Market, 2022 to 2032 in terms of value the market will surpass US$57.9 billion in 2022, our work calculates. We predict strong revenue growth through to 2032. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
How will the Anti-infective Vaccines Market, 2022 to 2032 report help you?
In summary, our 270+ page report provides you with the following knowledge:
• Revenue forecasts to 2032 for Anti-infective Vaccines Market, 2022 to 2032, with forecasts for disease type, product, and distribution channel each forecast at a global and regional level – discover the industry’s prospects, finding the most lucrative places for investments and revenues.
• Revenue forecasts to 2032 for five regional and 20 key national markets – See forecasts for the Anti-Infective Vaccines Market, 2022 to 2032 market in North America, Europe, Asia-Pacific and LAMEA. Also forecasted is the market in the U.S., Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.
• Prospects for established firms and those seeking to enter the market – including company profiles for 12 of the major companies involved in the Anti-Infective Vaccines Market, 2022 to 2032.
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.
Information found nowhere else
With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain’s study is for everybody needing commercial analyses for the Anti-Infective Vaccines Market, 2022 to 2032, market-leading companies. You will find data, trends and predictions.
To access the data contained in this document please email contactus@visiongain.com
Buy our report today Anti-infective Vaccines Market Report 2022-2032: Forecasts by Disease Type (Bacterial Diseases (Typhoid Vaccines, Tuberculosis Vaccines, Tetanus & Diphtheria Vaccines, Others), Viral Diseases (Influenza Vaccines, Hepatitis Vaccines, Polio Vaccine, Others)), by Product (Live/Attenuated Vaccines, Inactivated Vaccines, DNA & Recombinant Vector Vaccines, Others), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Others) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies AND COVID-19 Impact and Recovery Pattern Analysis. Avoid missing out by staying informed – order our report now.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: contactus@visiongain.com
1. Report Overview
1.1 Objectives of the Study
1.2 Introduction to Anti-infective Vaccines Market
1.3 What This Report Delivers
1.4 Why You Should Read This Report
1.5 Key Questions Answered By This Analytical Report Include:
1.6 Who is This Report For?
1.7 Methodology
1.7.1 Market Definitions
1.7.2 Market Evaluation & Forecasting Methodology
1.7.3 Data Validation
1.7.3.1 Primary Research
1.7.3.2 Secondary Research
1.8 Frequently Asked Questions (FAQs)
1.9 Associated Visiongain Reports
1.10 About Visiongain
2 Executive Summary
3 Market Overview
3.1 Key Findings
3.2 Market Dynamics
3.3 Market Driving Factors
3.3.1 Rising Focus and Government Support on Immunization Programs
3.3.2 Growing Investment in Vaccine Development
3.3.3 Increasing Company Initiatives to Enhance Vaccine R&D
3.3.4 High Prevalence of Infectious Diseases
3.3.5 Technological Advancements in Vaccine Administration
3.3.6 Strong Supply Backed Up by Robust R&D to Drive the Market
3.4 Market Restraining Factors
3.4.1 Inadequate Reimbursement Coverage
3.4.2 High Cost of Vaccine Development
3.4.3 Extended Timelines of Vaccine Manufacturing Hinder the Growth of the Vaccines Market
3.4.4 Stringent Government Regulations for Approval
3.4.5 Inadequate Access to Vaccines
3.5 Opportunities in the Global Market
3.5.1 High Growth Prospects in Emerging Markets
3.5.2 Focus on Therapeutic Vaccines
3.5.3 Use of Adjuvants in Vaccines
3.5.4 Government Support for Future Vaccine R&D
3.6 COVID-19 Impact Analysis
3.7 Porter’s Five Forces Analysis
3.7.1 Bargaining Power of Buyers: Low to Medium
3.7.2 Bargaining Power of Suppliers: High
3.7.3 Competitive Rivalry: Low to Medium
3.7.4 Threat of New Entrants: Low to Medium
3.7.5 Threat of Substitutes: Low
3.8 PEST Analysis
4 Global Anti-infective Vaccines Market Analysis by Disease Type
4.1 Key Findings
4.2 Disease Type Segment Growth Prospects
4.3 Global Anti-infective Vaccines Market Size Estimation and Forecast by Disease Type
4.4 Bacterial Diseases
4.4.1 Market Forecast by Region, 2022-2032 (US$ Mn)
4.4.2 Market Share by Region, 2022 & 2032 (%)
4.5 Viral Diseases
4.5.1 Market Forecast by Region, 2022-2032 (US$ Mn)
4.5.2 Market Share by Region, 2022 & 2032 (%)
5 Global Anti-infective Vaccines Market Analysis by Product
5.1 Key Findings
5.2 Product Segment Growth Prospects
5.3 Global Anti-infective Vaccines Market Size Estimation and Forecast by Product
5.4 Live/Attenuated Vaccines
5.4.1 Market Forecast by Region, 2022-2032 (US$ Mn)
5.4.2 Market Share by Region, 2022 & 2032 (%)
5.5 Inactivated Vaccines
5.5.1 Market Forecast by Region, 2022-2032 (US$ Mn)
5.5.2 Market Share by Region, 2022 & 2032 (%)
5.6 DNA & Recombinant Vector Vaccines
5.6.1 Market Forecast by Region, 2022-2032 (US$ Mn)
5.6.2 Market Share by Region, 2022 & 2032 (%)
5.7 Others
5.7.1 Market Forecast by Region, 2022-2032 (US$ Mn)
5.7.2 Market Share by Region, 2022 & 2032 (%)
6 Global Anti-infective Vaccines Market Analysis by Distribution Channel
6.1 Key Findings
6.2 Distribution Channel Segment Growth Prospects
6.3 Global Anti-infective Vaccines Market Size Estimation and Forecast by Distribution Channel
6.4 Hospital Pharmacy
6.4.1 Market Forecast by Region, 2022-2032 (US$ Mn)
6.4.2 Market Share by Region, 2022 & 2032 (%)
6.5 Retail Pharmacy
6.5.1 Market Forecast by Region, 2022-2032 (US$ Mn)
6.5.2 Market Share by Region, 2022 & 2032 (%)
6.6 Others
6.6.1 Market Forecast by Region, 2022-2032 (US$ Mn)
6.6.2 Market Share by Region, 2022 & 2032 (%)
7 Global Anti-infective Vaccines Market Analysis by Region
7.1 Key Findings
7.2 Regional Market Size Estimation and Forecast
7.3 COVID-19 Impact Analysis: Recovery Scenarios (V, U, W, L)
8 North America Anti-infective Vaccines Market Analysis
8.1 Key Findings
8.2 North America Anti-infective Vaccines Market Attractiveness Index
8.3 Market Size by Country, 2022, 2027 & 2032 (US$ Mn)
8.4 Market Size Estimation and Forecast by Country, 2022-2032 (US$ Mn)
8.5 Market Size Estimation and Forecast by Disease Type, 2022-2032 (US$ Mn)
8.5.1 Market Size Estimation and Forecast by Bacterial Diseases
8.5.2 Market Size Estimation and Forecast by Viral Diseases
8.6 Market Size Estimation and Forecast by Product, 2022-2032 (US$ Mn)
8.7 Market Size Estimation and Forecast by Distribution Channel, 2022-2032 (US$ Mn)
8.8 Market Size Estimation and Forecast by Country, 2022-2032 (US$ Mn)
8.8.1 U.S.
8.8.2 Canada
9 Europe Anti-infective Vaccines Market Analysis
9.1 Key Findings
9.2 Europe Anti-infective Vaccines Market Attractiveness Index
9.3 Market Size by Country, 2022, 2027 & 2032 (US$ Mn)
9.4 Market Size Estimation and Forecast by Country, 2022-2032 (US$ Mn)
9.5 Market Size Estimation and Forecast by Disease Type, 2022-2032 (US$ Mn)
9.5.1 Market Size Estimation and Forecast by Bacterial Diseases
9.5.2 Market Size Estimation and Forecast by Viral Diseases
9.6 Market Size Estimation and Forecast by Product, 2022-2032 (US$ Mn)
9.7 Market Size Estimation and Forecast by Distribution Channel, 2022-2032 (US$ Mn)
9.8 Market Size Estimation and Forecast by Country, 2022-2032 (US$ Mn)
9.8.1 Germany
9.8.2 UK
9.8.3 France
9.8.4 Italy
9.8.5 Spain
9.8.6 Russia
9.8.7 Rest of Europe
10 Asia Pacific Anti-infective Vaccines Market Analysis
10.1 Key Findings
10.2 Asia Pacific Anti-infective Vaccines Market Attractiveness Index
10.3 Market Size by Country, 2022, 2027 & 2032 (US$ Mn)
10.4 Market Size Estimation and Forecast by Country, 2022-2032 (US$ Mn)
10.5 Market Size Estimation and Forecast by Disease Type, 2022-2032 (US$ Mn)
10.5.1 Market Size Estimation and Forecast by Bacterial Diseases
10.5.2 Market Size Estimation and Forecast by Viral Diseases
10.6 Market Size Estimation and Forecast by Product, 2022-2032 (US$ Mn)
10.7 Market Size Estimation and Forecast by Distribution Channel, 2022-2032 (US$ Mn)
10.8 Market Size Estimation and Forecast by Country, 2022-2032 (US$ Mn)
10.8.1 Japan
10.8.2 China
10.8.3 India
10.8.4 Australia
10.8.5 Rest of Asia Pacific
11 Latin America Anti-infective Vaccines Market Analysis
11.1 Key Findings
11.2 Latin America Anti-infective Vaccines Market Attractiveness Index
11.3 Market Size by Country, 2022, 2027 & 2032 (US$ Mn)
11.4 Market Size Estimation and Forecast by Country, 2022-2032 (US$ Mn)
11.5 Market Size Estimation and Forecast by Disease Type, 2022-2032 (US$ Mn)
11.5.1 Market Size Estimation and Forecast by Bacterial Diseases
11.5.2 Market Size Estimation and Forecast by Viral Diseases
11.6 Market Size Estimation and Forecast by Product, 2022-2032 (US$ Mn)
11.7 Market Size Estimation and Forecast by Distribution Channel, 2022-2032 (US$ Mn)
11.8 Market Size Estimation and Forecast by Country, 2022-2032 (US$ Mn)
11.8.1 Brazil
11.8.2 Mexico
11.8.3 Rest of Latin America
12 MEA Anti-infective Vaccines Market Analysis
12.1 Key Findings
12.2 MEA Anti-infective Vaccines Market Attractiveness Index
12.3 Market Size by Country, 2022, 2027 & 2032 (US$ Mn)
12.4 Market Size Estimation and Forecast by Country, 2022-2032 (US$ Mn)
12.5 Market Size Estimation and Forecast by Disease Type, 2022-2032 (US$ Mn)
12.5.1 Market Size Estimation and Forecast by Bacterial Diseases
12.5.2 Market Size Estimation and Forecast by Viral Diseases
12.6 Market Size Estimation and Forecast by Product, 2022-2032 (US$ Mn)
12.7 Market Size Estimation and Forecast by Distribution Channel, 2022-2032 (US$ Mn)
12.8 Market Size Estimation and Forecast by Country, 2022-2032 (US$ Mn)
12.8.1 GCC
12.8.2 South Africa
12.8.3 Rest of MEA
13 Company Profiles
13.1 AstraZeneca PLC.
13.1.1 Company Snapshot
13.1.2 Company Overview
13.1.3 Financial Analysis
13.1.3.1 Net Revenue, 2016-2021
13.1.3.2 Regional Market Shares, 2021
13.1.3.3 Gross Profit, 2016-2021
13.1.3.4 R&D, 2016-2021
13.1.4 Product Benchmarking
13.1.5 Strategic Outlook
13.2 Bavarian Nordic
13.2.1 Company Snapshot
13.2.2 Company Overview
13.2.3 Financial Analysis
13.2.3.1 Net Revenue, 2016-2021
13.2.3.2 Regional Market Shares, 2021
13.2.3.3 Gross Profit, 2016-2021
13.2.3.4 R&D, 2016-2021
13.2.4 Product Benchmarking
13.2.5 Strategic Outlook
13.3 BioDiem
13.3.1 Company Snapshot
13.3.2 Company Overview
13.3.3 Financial Analysis
13.3.4 Product Benchmarking
13.3.5 Strategic Outlook
13.4 CSL Limited
13.4.1 Company Snapshot
13.4.2 Company Overview
13.4.3 Financial Analysis
13.4.3.1 Net Revenue, 2016-2021
13.4.3.2 Regional Market Shares, 2021
13.4.3.3 Gross Profit, 2016-2021
13.4.3.4 R&D, 2016-2021
13.4.4 Product Benchmarking
13.4.5 Strategic Outlook
13.5 Emergent BioSolutions Inc.
13.5.1 Company Snapshot
13.5.2 Company Overview
13.5.3 Financial Analysis
13.5.3.1 Net Revenue, 2016-2021
13.5.3.2 Gross Profit, 2016-2021
13.5.3.3 R&D, 2016-2021
13.5.4 Product Benchmarking
13.5.5 Strategic Outlook
13.6 Evotec
13.6.1 Company Snapshot
13.6.2 Company Overview
13.6.3 Financial Analysis
13.6.3.1 Net Revenue, 2016-2021
13.6.3.2 Regional Market Shares, 2021
13.6.3.3 Gross Profit, 2016-2021
13.6.3.4 R&D, 2016-2021
13.6.4 Product Benchmarking
13.6.5 Strategic Outlook
13.7 Merck & Co, Inc.
13.7.1 Company Snapshot
13.7.2 Company Overview
13.7.3 Financial Analysis
13.7.3.1 Net Revenue, 2016-2021
13.7.3.2 Regional Market Shares, 2021
13.7.3.3 Gross Profit, 2016-2021
13.7.3.4 R&D, 2016-2021
13.7.4 Product Benchmarking
13.7.5 Strategic Outlook
13.8 Mitsubishi Tanabe Pharma Corporation
13.8.1 Company Snapshot
13.8.2 Company Overview
13.8.3 Product Benchmarking
13.8.4 Strategic Outlook
13.9 Pfizer
13.9.1 Company Snapshot
13.9.2 Company Overview
13.9.3 Financial Analysis
13.9.3.1 Net Revenue, 2016-2021
13.9.3.2 Regional Market Shares, 2021
13.9.3.3 Gross Profit, 2016-2021
13.9.3.4 R&D, 2016-2021
13.9.4 Product Benchmarking
13.9.5 Strategic Outlook
13.10 Serum Institute of India Pvt. Ltd.
13.10.1 Company Snapshot
13.10.2 Company Overview
13.10.3 Product Benchmarking
13.10.4 Strategic Outlook
13.11 Sinovac Biotech Ltd.
13.11.1 Company Snapshot
13.11.2 Company Overview
13.11.3 Financial Analysis
13.11.3.1 Net Revenue, 2016-2021
13.11.3.2 Gross Profit, 2016-2021
13.11.3.3 R&D, 2016-2021
13.11.4 Product Benchmarking
13.12 Valneva SE
13.12.1 Company Snapshot
13.12.2 Company Overview
13.12.3 Financial Analysis
13.12.3.1 Net Revenue, 2016-2021
13.12.4 Product Benchmarking
13.12.5 Strategic Outlook
14 Conclusion and Recommendations
14.1 Concluding Remarks from Visiongain
14.2 Recommendations for Market Players
List of Tables
Table 1 Global Anti-infective Vaccines Market Snapshot, 2022 & 2032 (US$ billion, CAGR %)
Table 2 Global Anti-infective Vaccines Market Forecast by Region, 2022-2032 (US$ million, AGR%, CAGR%): "V" Shaped Recovery
Table 3 Global Anti-infective Vaccines Market Forecast by Region, 2022-2032 (US$ million, AGR%, CAGR%): "U" Shaped Recovery
Table 4 Global Anti-infective Vaccines Market Forecast by Region, 2022-2032 (US$ million, AGR%, CAGR%): "W" Shaped Recovery
Table 5 Global Anti-infective Vaccines Market Forecast by Region, 2022-2032 (US$ million, AGR%, CAGR%): "L" Shaped Recovery
Table 6 Global Anti-infective Vaccines Market Forecast by Disease Type, 2022-2032 (US$ million, AGR%, CAGR %)
Table 7 Bacterial Diseases Market Forecast by Region, 2022-2032 (US$ million, AGR%, CAGR %)
Table 8 Viral Diseases Market Forecast by Region, 2022-2032 (US$ million, AGR%, CAGR %)
Table 9 Global Anti-infective Vaccines Market Forecast by Product Type, 2022-2032 (US$ million, AGR%, CAGR %)
Table 10 Live/Attenuated Vaccines Market Forecast by Region, 2022-2032 (US$ million, AGR%, CAGR %)
Table 11 Major Whole Inactivated Virus COVID-19 Vaccine
Table 12 Inactivated Vaccines Market Forecast by Region, 2022-2032 (US$ million, AGR%, CAGR %)
Table 13 DNA Vaccines for Global COVID-19: Global Status
Table 14 DNA & Recombinant Vector Vaccines Market Forecast by Region, 2022-2032 (US$ million, AGR%, CAGR %)
Table 15 Others Market Forecast by Region, 2022-2032 (US$ million, AGR%, CAGR %)
Table 16 Global Anti-infective Vaccines Market Forecast by Distribution Channel, 2022-2032 (US$ million, AGR%, CAGR %)
Table 17 Hospital Pharmacy Market Forecast by Region, 2022-2032 (US$ million, AGR%, CAGR %)
Table 18 Retail Pharmacy Market Forecast by Region, 2022-2032 (US$ million, AGR%, CAGR %)
Table 19 Others Market Forecast by Region, 2022-2032 (US$ million, AGR%, CAGR %)
Table 20 Global Anti-infective Vaccines Market Forecast by Region, 2022-2032 (US$ million, AGR%, CAGR %)
Table 21 Global Anti-infective Vaccines Market Forecast by Region, 2022-2032 (US$ million, AGR%, CAGR%): "V" Shaped Recovery
Table 22 Global Anti-infective Vaccines Market Forecast by Region, 2022-2032 (US$ million, AGR%, CAGR%): "U" Shaped Recovery
Table 23 Global Anti-infective Vaccines Market Forecast by Region, 2022-2032 (US$ million, AGR%, CAGR%): "W" Shaped Recovery
Table 24 Global Anti-infective Vaccines Market Forecast by Region, 2022-2032 (US$ million, AGR%, CAGR%): "L" Shaped Recovery
Table 25 North America Anti-infective Vaccines Market Forecast by Country, 2022-2032 (US$ million, AGR%, CAGR %)
Table 26 North America Anti-infective Vaccines Market Forecast by Disease Type, 2022-2032 (US$ million, AGR%, CAGR %)
Table 27 North America Anti-infective Vaccines Market Forecast by Bacterial Diseases, 2022-2032 (US$ million, AGR%, CAGR %)
Table 28 North America Anti-infective Vaccines Market Forecast by Viral Diseases, 2022-2032 (US$ million, AGR%, CAGR %)
Table 29 North America Anti-infective Vaccines Market Forecast by Product Type, 2022-2032 (US$ million, AGR%, CAGR %)
Table 30 North America Anti-infective Vaccines Market Forecast by Distribution Channel, 2022-2032 (US$ million, AGR%, CAGR %)
Table 31 U.S Anti-infective Vaccines Market Forecast by Country, 2022-2032 (US$ million, AGR%, CAGR %)
Table 32 Canada Anti-infective Vaccines Market Forecast by Country, 2022-2032 (US$ million, AGR%, CAGR %)
Table 33 Europe Anti-infective Vaccines Market Forecast by Country, 2022-2032 (US$ million, AGR%, CAGR %)
Table 34 Europe Anti-infective Vaccines Market Forecast by Disease Type, 2022-2032 (US$ million, AGR%, CAGR %)
Table 35 Europe Anti-infective Vaccines Market Forecast by Bacterial Diseases, 2022-2032 (US$ million, AGR%, CAGR %)
Table 36 Europe Anti-infective Vaccines Market Forecast by Viral Diseases, 2022-2032 (US$ million, AGR%, CAGR %)
Table 37 Europe Anti-infective Vaccines Market Forecast by Product Type, 2022-2032 (US$ million, AGR%, CAGR %)
Table 38 Europe Anti-infective Vaccines Market Forecast by Distribution Channel, 2022-2032 (US$ million, AGR%, CAGR %)
Table 39 Germany Anti-infective Vaccines Market Forecast by Country, 2022-2032 (US$ million, AGR%, CAGR %)
Table 40 UK Anti-infective Vaccines Market Forecast by Country, 2022-2032 (US$ million, AGR%, CAGR %)
Table 41 France Anti-infective Vaccines Market Forecast by Country, 2022-2032 (US$ million, AGR%, CAGR %)
Table 42 Italy Anti-infective Vaccines Market Forecast by Country, 2022-2032 (US$ million, AGR%, CAGR %)
Table 43 Spain Anti-infective Vaccines Market Forecast by Country, 2022-2032 (US$ million, AGR%, CAGR %)
Table 44 Russia Anti-infective Vaccines Market Forecast by Country, 2022-2032 (US$ million, AGR%, CAGR %)
Table 45 Rest of Europe Anti-infective Vaccines Market Forecast by Country, 2022-2032 (US$ million, AGR%, CAGR %)
Table 46 Asia Pacific Anti-infective Vaccines Market Forecast by Country, 2022-2032 (US$ million, AGR%, CAGR %)
Table 47 Asia Pacific Anti-infective Vaccines Market Forecast by Disease Type, 2022-2032 (US$ million, AGR%, CAGR %)
Table 48 Asia Pacific Anti-infective Vaccines Market Forecast by Bacterial Diseases, 2022-2032 (US$ million, AGR%, CAGR %)
Table 49 Asia Pacific Anti-infective Vaccines Market Forecast by Viral Diseases, 2022-2032 (US$ million, AGR%, CAGR %)
Table 50 Asia Pacific Anti-infective Vaccines Market Forecast by Product Type, 2022-2032 (US$ million, AGR%, CAGR %)
Table 51 Asia Pacific Anti-infective Vaccines Market Forecast by Distribution Channel, 2022-2032 (US$ million, AGR%, CAGR %)
Table 52 Japan Anti-infective Vaccines Market Forecast by Country, 2022-2032 (US$ million, AGR%, CAGR %)
Table 53 China Anti-infective Vaccines Market Forecast by Country, 2022-2032 (US$ million, AGR%, CAGR %)
Table 54 India Anti-infective Vaccines Market Forecast by Country, 2022-2032 (US$ million, AGR%, CAGR %)
Table 55 Australia Anti-infective Vaccines Market Forecast by Country, 2022-2032 (US$ million, AGR%, CAGR %)
Table 56 Rest of Asia Pacific Anti-infective Vaccines Market Forecast by Country, 2022-2032 (US$ million, AGR%, CAGR %)
Table 57 Latin America Anti-infective Vaccines Market Forecast by Country, 2022-2032 (US$ million, AGR%, CAGR %)
Table 58 Latin America Anti-infective Vaccines Market Forecast by Disease Type, 2022-2032 (US$ million, AGR%, CAGR %)
Table 59 Latin America Anti-infective Vaccines Market Forecast by Bacterial Diseases, 2022-2032 (US$ million, AGR%, CAGR %)
Table 60 Latin America Anti-infective Vaccines Market Forecast by Viral Diseases, 2022-2032 (US$ million, AGR%, CAGR %)
Table 61 Latin America Anti-infective Vaccines Market Forecast by Product Type, 2022-2032 (US$ million, AGR%, CAGR %)
Table 62 Latin America Anti-infective Vaccines Market Forecast by Distribution Channel, 2022-2032 (US$ million, AGR%, CAGR %)
Table 63 Brazil Anti-infective Vaccines Market Forecast by Country, 2022-2032 (US$ million, AGR%, CAGR %)
Table 64 Mexico Anti-infective Vaccines Market Forecast by Country, 2022-2032 (US$ million, AGR%, CAGR %)
Table 65 Rest of Latin America Anti-infective Vaccines Market Forecast by Country, 2022-2032 (US$ million, AGR%, CAGR %)
Table 66 MEA Anti-infective Vaccines Market Forecast by Country, 2022-2032 (US$ million, AGR%, CAGR %)
Table 67 MEA Anti-infective Vaccines Market Forecast by Disease Type, 2022-2032 (US$ million, AGR%, CAGR %)
Table 68 MEA Anti-infective Vaccines Market Forecast by Bacterial Diseases, 2022-2032 (US$ million, AGR%, CAGR %)
Table 69 MEA Anti-infective Vaccines Market Forecast by Viral Diseases, 2022-2032 (US$ million, AGR%, CAGR %)
Table 70 MEA Anti-infective Vaccines Market Forecast by Product Type, 2022-2032 (US$ million, AGR%, CAGR %)
Table 71 MEA Anti-infective Vaccines Market Forecast by Distribution Channel, 2022-2032 (US$ million, AGR%, CAGR %)
Table 72 GCC Anti-infective Vaccines Market Forecast by Country, 2022-2032 (US$ million, AGR%, CAGR %)
Table 73 South Africa Anti-infective Vaccines Market Forecast by Country, 2022-2032 (US$ million, AGR%, CAGR %)
Table 74 MEA Anti-infective Vaccines Market Forecast by Country, 2022-2032 (US$ million, AGR%, CAGR %)
Table 75 AstraZeneca: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 76 AstraZeneca: Product Benchmarking
Table 77 AstraZeneca: Strategic Outlook
Table 78 Bavarian Nordic: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 79 Bavarian Nordic: Product Benchmarking
Table 80 Bavarian Nordic: Strategic Outlook
Table 81 BioDiem: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 82 BioDiem: Product Benchmarking
Table 83 CSL Limited: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 84 CSL Limited: Product Benchmarking
Table 85 CSL Limited: Strategic Outlook
Table 86 Emergent BioSolutions Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 87 Emergent BioSolutions Inc.: Product Benchmarking
Table 88 Emergent BioSolutions Inc.: Strategic Outlook
Table 89 Evotec: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 90 Evotec: Product Benchmarking
Table 91 Evotec: Strategic Outlook
Table 92 Merck & Co, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 93 Merck & Co, Inc.: Product Benchmarking
Table 94 Merck & Co, Inc.: Strategic Outlook
Table 95 Mitsubishi Tanabe Pharma Corporation: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 96 Mitsubishi Tanabe Pharma Corporation: Product Benchmarking
Table 97 Mitsubishi Tanabe Pharma Corporation: Strategic Outlook
Table 98 Pfizer: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 99 Pfizer: Product Benchmarking
Table 100 Pfizer: Strategic Outlook
Table 101 Serum Institute of India Pvt. Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 102 Serum Institute of India Pvt. Ltd.: Product Benchmarking
Table 103 Serum Institute of India Pvt. Ltd.: Strategic Outlook
Table 104 Sinovac Biotech Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 105 Sinovac Biotech Ltd.: Product Benchmarking
Table 106 Valneva SE: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 107 Valneva SE: Product Benchmarking
Table 108 Valneva SE: Strategic Outlook
List of Figures
Figure 1 Global Anti-infective Vaccines Market Segmentation
Figure 2 Global Anti-infective Vaccines Market Attractiveness Index by Region
Figure 3 Global Anti-infective Vaccines Market by Disease Type: Market Attractiveness Index
Figure 4 Global Anti-infective Vaccines Market by Product: Market Attractiveness Index
Figure 5 Global Anti-infective Vaccines Market by Distribution Channel: Market Attractiveness Index
Figure 6 Global Anti-infective Vaccines Market: Market Dynamics
Figure 7 Global COVID Impact Analysis: Anti-infective Vaccines Market Recovery Scenarios
Figure 8 Global Anti-infective Vaccines Market by Region, 2022-2032 (US$ Mn, AGR (%), CAGR (%)): “V” Shaped Recovery
Figure 9 Global Anti-infective Vaccines Market by Region, 2022-2032 (US$ Mn, AGR (%), CAGR (%)): “U” Shaped Recovery
Figure 10 Global Anti-infective Vaccines Market by Region, 2022-2032 (US$ Mn, AGR (%), CAGR (%)): “W” Shaped Recovery
Figure 11 Global Anti-infective Vaccines Market by Region, 2022-2032 (US$ Mn, AGR (%), CAGR (%)): “L” Shaped Recovery
Figure 12 Global Anti-infective Vaccines Market: Porter’s Five Forces Analysis
Figure 13 Global Anti-infective Vaccines Market: PEST Analysis
Figure 14 Global Anti-infective Vaccines Market Attractiveness Index by Disease Type
Figure 15 Global Anti-infective Vaccines Market Forecast by Disease Type, 2022-2032 (US$ million)
Figure 16 Global Anti-infective Vaccines Market Share Forecast by Disease Type, 2022, 2027, 2032 (%)
Figure 17 Bacterial Diseases Market Forecast by Region, 2022-2032 (US$ million)
Figure 18 Bacterial Diseases Market Share Forecast by Region, 2022 & 2032 (%)
Figure 19 Viral Diseases Market Forecast by Region, 2022-2032 (US$ million)
Figure 20 Viral Diseases Market Share Forecast by Region, 2022 & 2032 (%)
Figure 21 Global Anti-infective Vaccines Market Attractiveness Index by Disease Type
Figure 22 Global Anti-infective Vaccines Market Forecast by Product, 2022-2032 (US$ million)
Figure 23 Global Anti-infective Vaccines Market Share Forecast by Product, 2022, 2027, 2032 (%)
Figure 24 Live/Attenuated Vaccines Market Forecast by Region, 2022-2032 (US$ million)
Figure 25 Live/Attenuated Vaccines Market Share Forecast by Region, 2022 & 2032 (%)
Figure 26 Inactivated Vaccines Market Forecast by Region, 2022-2032 (US$ million)
Figure 27 Inactivated Vaccines Market Share Forecast by Region, 2022 & 2032 (%)
Figure 28 DNA & Recombinant Vector Vaccines Market Forecast by Region, 2022-2032 (US$ million)
Figure 29 DNA & Recombinant Vector Vaccines Market Share Forecast by Region, 2022 & 2032 (%)
Figure 30 Others Market Forecast by Region, 2022-2032 (US$ million)
Figure 31 Others Market Share Forecast by Region, 2022 & 2032 (%)
Figure 32 Global Anti-infective Vaccines Market Attractiveness Index by Distribution Channel
Figure 33 Global Anti-infective Vaccines Market Forecast by Distribution Channel, 2022-2032 (US$ million)
Figure 34 Global Anti-infective Vaccines Market Share Forecast by Distribution Channel, 2022, 2027, 2032 (%)
Figure 35 Hospital Pharmacy Market Forecast by Region, 2022-2032 (US$ million)
Figure 36 Hospital Pharmacy Market Share Forecast by Region, 2022 & 2032 (%)
Figure 37 Retail Pharmacy Market Forecast by Region, 2022-2032 (US$ million)
Figure 38 Retail Pharmacy Market Share Forecast by Region, 2022 & 2032 (%)
Figure 39 Others Market Forecast by Region, 2022-2032 (US$ million)
Figure 40 Others Market Share Forecast by Region, 2022 & 2032 (%)
Figure 41 Global Anti-infective Vaccines Market Forecast by Region 2022, 2027, 2032 (Revenue, CAGR %)
Figure 42 Global Anti-infective Vaccines Market Share Forecast by Region 2022, 2027, 2032(%)
Figure 43 Global Anti-infective Vaccines Market by Region, 2022-2032 (US$ Mn, AGR (%), CAGR (%))
Figure 44 Global Anti-infective Vaccines Market by Region, 2022-2032 (US$ Mn, AGR (%), CAGR (%)): “V” Shaped Recovery
Figure 45 Global Anti-infective Vaccines Market by Region, 2022-2032 (US$ Mn, AGR (%), CAGR (%)): “U” Shaped Recovery
Figure 46 Global Anti-infective Vaccines Market by Region, 2022-2032 (US$ Mn, AGR (%), CAGR (%)): “W” Shaped Recovery
Figure 47 Global Anti-infective Vaccines Market by Region, 2022-2032 (US$ Mn, AGR (%), CAGR (%)): “L” Shaped Recovery
Figure 48 North America Anti-infective Vaccines Market Attractiveness Index
Figure 49 North America Anti-infective Vaccines Market by Region, 2022, 2027 & 2032 (US$ million)
Figure 50 North America Anti-infective Vaccines Market Forecast by Country, 2022-2032 (US$ million)
Figure 51 North America Anti-infective Vaccines Market Share Forecast by Country, 2022 & 2032 (%)
Figure 52 North America Anti-infective Vaccines Market Forecast by Disease Type, 2022-2032 (US$ million)
Figure 53 North America Anti-infective Vaccines Market Share Forecast by Disease Type, 2022 & 2032 (%)
Figure 54 North America Anti-infective Vaccines Market Forecast by Bacterial Diseases, 2022-2032 (US$ million)
Figure 55 North America Anti-infective Vaccines Market Share Forecast by Bacterial Diseases, 2022 & 2032 (%)
Figure 56 North America Anti-infective Vaccines Market Forecast by Viral Diseases, 2022-2032 (US$ million)
Figure 57 North America Anti-infective Vaccines Market Share Forecast by Viral Diseases, 2022 & 2032 (%)
Figure 58 North America Anti-infective Vaccines Market Forecast by Product, 2022-2032 (US$ million)
Figure 59 North America Anti-infective Vaccines Market Share Forecast by Product, 2022 & 2032 (%)
Figure 60 North America Anti-infective Vaccines Market Forecast by Distribution Channel, 2022-2032 (US$ million)
Figure 61 North America Anti-infective Vaccines Market Share Forecast by Distribution Channel, 2022 & 2032 (%)
Figure 62 U.S. Anti-infective Vaccines Market Forecast, 2022-2032 (US$ million)
Figure 63 Canada Anti-infective Vaccines Market Forecast, 2022-2032 (US$ million)
Figure 64 Europe Anti-infective Vaccines Market Attractiveness Index
Figure 65 Europe Anti-infective Vaccines Market by Region, 2022, 2027 & 2032 (US$ million)
Figure 66 Europe Anti-infective Vaccines Market Forecast by Country, 2022-2032 (US$ million)
Figure 67 Europe Anti-infective Vaccines Market Share Forecast by Country, 2022 & 2032 (%)
Figure 68 Europe Anti-infective Vaccines Market Forecast by Disease Type, 2022-2032 (US$ million)
Figure 69 Europe Anti-infective Vaccines Market Share Forecast by Disease Type, 2022 & 2032 (%)
Figure 70 Europe Anti-infective Vaccines Market Forecast by Bacterial Diseases, 2022-2032 (US$ million)
Figure 71 Europe Anti-infective Vaccines Market Share Forecast by Bacterial Diseases, 2022 & 2032 (%)
Figure 72 Europe Anti-infective Vaccines Market Forecast by Viral Diseases, 2022-2032 (US$ million)
Figure 73 Europe Anti-infective Vaccines Market Share Forecast by Viral Diseases, 2022 & 2032 (%)
Figure 74 Europe Anti-infective Vaccines Market Forecast by Product, 2022-2032 (US$ million)
Figure 75 Europe Anti-infective Vaccines Market Share Forecast by Product, 2022 & 2032 (%)
Figure 76 Europe Anti-infective Vaccines Market Forecast by Distribution Channel, 2022-2032 (US$ million)
Figure 77 Europe Anti-infective Vaccines Market Share Forecast by Distribution Channel, 2022 & 2032 (%)
Figure 78 Germany Anti-infective Vaccines Market Forecast, 2022-2032 (US$ million)
Figure 79 UK Anti-infective Vaccines Market Forecast, 2022-2032 (US$ million)
Figure 80 France Anti-infective Vaccines Market Forecast, 2022-2032 (US$ million)
Figure 81 Italy Anti-infective Vaccines Market Forecast, 2022-2032 (US$ million)
Figure 82 Spain Anti-infective Vaccines Market Forecast, 2022-2032 (US$ million)
Figure 83 Russia Anti-infective Vaccines Market Forecast, 2022-2032 (US$ million)
Figure 84 Rest of Europe Anti-infective Vaccines Market Forecast, 2022-2032 (US$ million)
Figure 85 Asia Pacific Anti-infective Vaccines Market Attractiveness Index
Figure 86 Asia Pacific Anti-infective Vaccines Market by Region, 2022, 2027 & 2032 (US$ million)
Figure 87 Asia Pacific Anti-infective Vaccines Market Forecast by Country, 2022-2032 (US$ million)
Figure 88 Asia Pacific Anti-infective Vaccines Market Share Forecast by Country, 2022 & 2032 (%)
Figure 89 Asia Pacific Anti-infective Vaccines Market Forecast by Disease Type, 2022-2032 (US$ million)
Figure 90 Asia Pacific Anti-infective Vaccines Market Share Forecast by Disease Type, 2022 & 2032 (%)
Figure 91 Asia Pacific Anti-infective Vaccines Market Forecast by Bacterial Diseases, 2022-2032 (US$ million)
Figure 92 Asia Pacific Anti-infective Vaccines Market Share Forecast by Bacterial Diseases, 2022 & 2032 (%)
Figure 93 Asia Pacific Anti-infective Vaccines Market Forecast by Viral Diseases, 2022-2032 (US$ million)
Figure 94 Asia Pacific Anti-infective Vaccines Market Share Forecast by Viral Diseases, 2022 & 2032 (%)
Figure 95 Asia Pacific Anti-infective Vaccines Market Forecast by Product, 2022-2032 (US$ million)
Figure 96 Asia Pacific Anti-infective Vaccines Market Share Forecast by Product, 2022 & 2032 (%)
Figure 97 Asia Pacific Anti-infective Vaccines Market Forecast by Distribution Channel, 2022-2032 (US$ million)
Figure 98 Asia Pacific Anti-infective Vaccines Market Share Forecast by Distribution Channel, 2022 & 2032 (%)
Figure 99 Japan Anti-infective Vaccines Market Forecast, 2022-2032 (US$ million)
Figure 100 China Anti-infective Vaccines Market Forecast, 2022-2032 (US$ million)
Figure 101 India Anti-infective Vaccines Market Forecast, 2022-2032 (US$ million)
Figure 102 Australia Anti-infective Vaccines Market Forecast, 2022-2032 (US$ million)
Figure 103 Rest of Asia Pacific Anti-infective Vaccines Market Forecast, 2022-2032 (US$ million)
Figure 104 Latin America Anti-infective Vaccines Market Attractiveness Index
Figure 105 Latin America Anti-infective Vaccines Market by Region, 2022, 2027 & 2032 (US$ million)
Figure 106 Latin America Anti-infective Vaccines Market Forecast by Country, 2022-2032 (US$ million)
Figure 107 Latin America Anti-infective Vaccines Market Share Forecast by Country, 2022 & 2032 (%)
Figure 108 Latin America Anti-infective Vaccines Market Forecast by Disease Type, 2022-2032 (US$ million)
Figure 109 Latin America Anti-infective Vaccines Market Share Forecast by Disease Type, 2022 & 2032 (%)
Figure 110 Latin America Anti-infective Vaccines Market Forecast by Bacterial Diseases, 2022-2032 (US$ million)
Figure 111 Latin America Anti-infective Vaccines Market Share Forecast by Bacterial Diseases, 2022 & 2032 (%)
Figure 112 Latin America Anti-infective Vaccines Market Forecast by Viral Diseases, 2022-2032 (US$ million)
Figure 113 Latin America Anti-infective Vaccines Market Share Forecast by Viral Diseases, 2022 & 2032 (%)
Figure 114 Latin America Anti-infective Vaccines Market Forecast by Product, 2022-2032 (US$ million)
Figure 115 Latin America Anti-infective Vaccines Market Share Forecast by Product, 2022 & 2032 (%)
Figure 116 Latin America Anti-infective Vaccines Market Forecast by Distribution Channel, 2022-2032 (US$ million)
Figure 117 Latin America Anti-infective Vaccines Market Share Forecast by Distribution Channel, 2022 & 2032 (%)
Figure 118 Brazil Anti-infective Vaccines Market Forecast, 2022-2032 (US$ million)
Figure 119 Mexico Anti-infective Vaccines Market Forecast, 2022-2032 (US$ million)
Figure 120 Rest of Latin America Anti-infective Vaccines Market Forecast, 2022-2032 (US$ million)
Figure 121 MEA Anti-infective Vaccines Market Attractiveness Index
Figure 122 MEA Anti-infective Vaccines Market by Region, 2022, 2027 & 2032 (US$ million)
Figure 123 MEA Anti-infective Vaccines Market Forecast by Country, 2022-2032 (US$ million)
Figure 124 MEA Anti-infective Vaccines Market Share Forecast by Country, 2022 & 2032 (%)
Figure 125 MEA Anti-infective Vaccines Market Forecast by Disease Type, 2022-2032 (US$ million)
Figure 126 MEA Anti-infective Vaccines Market Share Forecast by Disease Type, 2022 & 2032 (%)
Figure 127 MEA Anti-infective Vaccines Market Forecast by Bacterial Diseases, 2022-2032 (US$ million)
Figure 128 MEA Anti-infective Vaccines Market Share Forecast by Bacterial Diseases, 2022 & 2032 (%)
Figure 129 MEA Anti-infective Vaccines Market Forecast by Viral Diseases, 2022-2032 (US$ million)
Figure 130 MEA Anti-infective Vaccines Market Share Forecast by Viral Diseases, 2022 & 2032 (%)
Figure 131 MEA Anti-infective Vaccines Market Forecast by Product, 2022-2032 (US$ million)
Figure 132 MEA Anti-infective Vaccines Market Share Forecast by Product, 2022 & 2032 (%)
Figure 133 MEA Anti-infective Vaccines Market Forecast by Distribution Channel, 2022-2032 (US$ million)
Figure 134 MEA Anti-infective Vaccines Market Share Forecast by Distribution Channel, 2022 & 2032 (%)
Figure 135 GCC Anti-infective Vaccines Market Forecast, 2022-2032 (US$ million)
Figure 136 South Africa Anti-infective Vaccines Market Forecast, 2022-2032 (US$ million)
Figure 137 Rest of MEA Anti-infective Vaccines Market Forecast, 2022-2032 (US$ million)
Figure 138 AstraZeneca: Net Revenue, 2016-2021 (US$ million, AGR %)
Figure 139 AstraZeneca: Regional Market Shares, 2021
Figure 140 AstraZeneca: Gross Profit, 2016-2021 (US$ million, AGR %)
Figure 141 AstraZeneca: R&D, 2016-2021 (US$ million, AGR %)
Figure 142 Bavarian Nordic: Net Revenue, 2016-2021 (US$ million, AGR %)
Figure 143 Bavarian Nordic: Regional Market Shares, 2021
Figure 144 Bavarian Nordic: Gross Profit, 2016-2021 (US$ million, AGR %)
Figure 145 Bavarian Nordic: R&D, 2016-2021 (US$ million, AGR %)
Figure 146 CSL Limited: Net Revenue, 2016-2021 (US$ million, AGR %)
Figure 147 CSL Limited: Regional Market Shares, 2021
Figure 148 CSL Limited: Gross Profit, 2016-2021 (US$ million, AGR %)
Figure 149 CSL Limited: R&D, 2016-2021 (US$ million, AGR %)
Figure 150 Emergent BioSolutions Inc.: Net Revenue, 2016-2021 (US$ million, AGR %)
Figure 151 Emergent BioSolutions Inc.: Gross Profit, 2016-2021 (US$ million, AGR %)
Figure 152 Emergent BioSolutions Inc.: R&D, 2016-2021 (US$ million, AGR %)
Figure 153 Evotec: Net Revenue, 2016-2021 (US$ million, AGR %)
Figure 154 Evotec: Regional Market Shares, 2021
Figure 155 Evotec: Gross Profit, 2016-2021 (US$ million, AGR %)
Figure 156 Evotec: R&D, 2016-2021 (US$ million, AGR %)
Figure 157 Merck & Co, Inc.: Net Revenue, 2016-2021 (US$ million, AGR %)
Figure 158 Merck & Co, Inc.: Regional Market Shares, 2021
Figure 159 Merck & Co, Inc.: Gross Profit, 2016-2021 (US$ million, AGR %)
Figure 160 Merck & Co, Inc.: R&D, 2016-2021 (US$ million, AGR %)
Figure 161 Pfizer: Net Revenue, 2016-2021 (US$ million, AGR%)
Figure 162 Pfizer: Regional Market Shares, 2021
Figure 163 Pfizer: Gross Profit, 2016-2021 (US$ million, AGR%)
Figure 164 Pfizer: R&D, 2016-2021 (US$ million, AGR%)
Figure 165 Sinovac Biotech Ltd.: Net Revenue, 2016-2021 (US$ million, AGR %)
Figure 166 Sinovac Biotech Ltd.: Gross Profit, 2016-2021 (US$ million, AGR %)
Figure 167 Sinovac Biotech Ltd.: R&D, 2016-2021 (US$ million, AGR %)
Figure 168 Valneva SE: Net Revenue, 2016-2021 (US$ million, AGR %)
Figure 169 Global Anti-infective Vaccines Market Forecast by Region 2022, 2027, 2032 (Revenue, CAGR %)
Figure 170 Global Anti-infective Vaccines Market Share Forecast by Region 2022, 2027, 2032 (%)
List of Companies Profiled in the Report
AstraZeneca Plc.
Bavarian Nordic
BioDiem Ltd.,
CSL Limited
Emergent BioSolutions Inc.
Evotec
Merck & Co, Inc.
Mitsubishi Tanabe Pharma Corporation
Pfizer
Serum Institute of India Pvt. Ltd.
Sinovac Biotech Ltd.
Valneva SE
List of Other Companies Mentioned in the Report
Affinivax, Inc.
Alydia Health
Astex Pharmaceuticals
Bayer AG
Batavia Biosciences
BB-NCIPD (Bul Bio)
Bharat Biotech
Biocon Biologics Limited (BBL)
BIOFABRI
Bristol Myers Squibb
Centogene N.V.
Chimerix, Inc.
China National Biotec Group
Chinook Therapeutics, Inc.
Dr. Reddy’s Laboratories Ltd.
Dynavax Technologies Corporation
Exothera
Gland Pharma
GSK plc
Hetero Biopharma
IDT Biologika
Johnson & Johnson
Moderna
Morepen
Novavax, Inc.
Novo Nordisk
Ocugen
Panacea Biotec
ReiThera Srl
Resolute Therapeutics
Secarna Pharmaceuticals GmbH & Co. KG
Seqirus
Stablepharma
Stelis Biopharma
Taiho Pharmaceutical Co, Ltd.
Takeda Pharmaceutical
uniQure NV
Valneva SE
Virchow Biotech
List of Associations Mentioned in the Report
Biomedical Advanced Research and Development Authority (BARDA)
Centers for Disease Control and Prevention (CDC)
Coalition for Epidemic Preparedness Innovations (CEPI)
Committee for Medicinal Products for Human Use (CHMP)
European Commission (EC)
European Medicines Agency (EMA)
Food and Drug Administration (FDA)
GAVI
Haute Autorité de santé (HAS)
Indian Council of Medical Research (ICMR)
International AIDS Vaccine Initiative (IAVI)
King Abdulaziz University (KAU)
Medicines and Healthcare products Regulatory Agency (MHRA)
National Health Service (NHS)
National Institute of Virology (NIV)
Russian Direct Investment Fund (RDIF)
Servizio Sanitario Nazionale (SSN)
United Nations Children's Fund (UNICEF)
University of Saskatchewan (USask, Canada)
University of Zaragoza
US Department of Health and Human Services (HHS)
Vaccine and Infectious Disease Organization (VIDO)
World Health Organization (WHO)
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
